Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has had SARS-CoV-2 positive antigen, RT-PCR, or other locally approved molecular diagnostic assay obtained within 5 days prior to randomization~* Has had symptoms consistent with COVID-19 with onset 5 days before randomization~* Has one or more COVID-19-related signs or symptoms on the day of randomization~* Phase 2: Is an adult aged 18 years and above~* Phase 3: Is an adult aged 18 years and above or is an adolescent aged 12 to 17 years (inclusive) and weighing ≥40 kg at the time of screening~Exclusion Criteria:~* Is currently hospitalized or in the opinion of the investigator is anticipated to require hospitalization within 48 hours of randomization.~* Has severe COVID-19 or is on supplemental oxygen~* Has a history of a positive SARS-CoV-2 antibody serology test~* Has participated, within the last 30 days, in a clinical study involving an investigational intervention~* Has received a SARS-CoV-2 vaccine, monoclonal antibody, or plasma from a person who recovered from COVID-19 any time prior to participation in the study~NOTE: Other protocol defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ADG20 IM (Type: EXPERIMENTAL): Participants will be dosed on Day 1 with ADG20 IM
- Placebo IM (Type: PLACEBO_COMPARATOR): Participants will be dosed on Day 1 with placebo IM

Based on this trial design, predict the completion outcome and termination type (if applicable).